Nektar Therapeutics (NKTR) Draws Fresh Eczema Buzz Following A 72% Undervalued Narrative

Simply Wall St.11-07

Nektar Therapeutics (NKTR) has drawn fresh attention after its eczema and hair loss drug candidate, positioned as an alternative for patients who do not respond to Dupixent, emerged as a key focus for...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681811078?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","is_english":true,"pubTime":"2026-11-07 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681811078","market":"nz","top_or_hot":-1,"title":"Nektar Therapeutics (NKTR) Draws Fresh Eczema Buzz Following A 72% Undervalued Narrative","media":"Simply Wall St.","content":"<div>\n<p>Nektar Therapeutics (NKTR) has drawn fresh attention after its eczema and hair loss drug candidate, positioned as an alternative for patients who do not respond to Dupixent, emerged as a key focus for...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-draws-fresh-eczema-buzz-following-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics (NKTR) Draws Fresh Eczema Buzz Following A 72% Undervalued Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics (NKTR) Draws Fresh Eczema Buzz Following A 72% Undervalued Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-07 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-draws-fresh-eczema-buzz-following-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nektar Therapeutics (NKTR) has drawn fresh attention after its eczema and hair loss drug candidate, positioned as an alternative for patients who do not respond to Dupixent, emerged as a key focus for...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-draws-fresh-eczema-buzz-following-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-draws-fresh-eczema-buzz-following-a","article_id":"2681811078","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-draws-fresh-eczema-buzz-following-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681811078","pubTimestamp":1794040812,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗","BK4139":"生物科技"},"translate_title":"Nektar Therapeutics (NKTR) 在被低估 72% 的叙述后吸引了新的湿疹热议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1.5},"content_text":"Nektar Therapeutics (NKTR) has drawn fresh attention after its eczema and hair loss drug candidate, positioned as an alternative for patients who do not respond to Dupixent, emerged as a key focus for analysts. Despite new interest in its eczema and hair loss program, Nektar Therapeutics’ share price has been volatile. The 1-day share price return is 3.07%, but the 90-day share price return has fallen 51.28%, while the 3-year total shareholder return is 446.05%. This pattern suggests that earlier enthusiasm is now being reassessed in light of execution risks and valuation concerns. Spot emerging biopharma stories beyond Nektar Therapeutics by scanning a curated 19 high quality undiscovered gems featuring companies with strong fundamentals that the wider market may not be watching closely yet.\nAfter a three year surge and a sharp 90 day pullback, Nektar Therapeutics now splits opinion. Is the meaningful upside still ahead, or did most of it already play out in the rear-view mirror, as the valuation section shows next? AdvertisementMost Popular Narrative: 72% Undervalued Nektar Therapeutics closed at $37.26 while the most followed narrative anchors fair value at about $133.08. The entire debate hinges on whether rezpegaldesleukin and the broader pipeline can turn a development stage biotech with losses into a cash generative immunology platform by the late 2020s.  The reported pool of more than 15 million moderate to severe atopic dermatitis patients and roughly 6.7 million alopecia areata patients in the United States with relatively low current use of systemic therapies highlights substantial untreated demand that rezpegaldesleukin could address, with potential to scale Nektar Therapeutics’ top line and improve operating leverage if adoption materializes.  See why 13 investors see Nektar Therapeutics as 72% undervalued. Result: Fair Value of $133.08 (UNDERVALUED) Still, the narrative around Nektar Therapeutics could crack if late stage rezpegaldesleukin trials stumble, or if ongoing losses eventually force dilutive funding at weak prices. Find out about the key risks to this Nektar Therapeutics narrative. Another View: What Nektar Therapeutics Looks Like On Sales The analyst narrative points to Nektar Therapeutics trading 72% below a $133.08 fair value anchor. On a simpler yardstick, the current P/S ratio of 23.3x looks heavy next to both the US Biotechs industry at 10.1x and a fair ratio of 9.2x, which implies meaningful valuation risk if expectations cool further. Which lens do you trust more when the stock is already pricing in rich sales multiples? For readers who lean on comparative ratios rather than long range narratives, the gap between today’s P/S, peers and that lower fair ratio can be a useful reality check on how much optimism is already baked in, and whether rezpegaldesleukin has to clear a very high bar for the share price to keep up with the current tag, See what the numbers say about this price — find out in our valuation breakdown. NasdaqCM:NKTR P/S Ratio as at Nov 2026Next Steps Unsure whether the current mix of excitement and doubt around Nektar Therapeutics feels justified to you? Act quickly, review the data for yourself, and weigh both sides by starting with the 1 key reward and 3 important warning signs. Looking for more investment ideas beyond Nektar Therapeutics? If Nektar Therapeutics has you thinking harder about risk, reward, and timing, do not stop here. Use the screener to surface fresh opportunities that fit your style.  Target potential bargains early by scanning a curated pool of 19 high quality undiscovered gems that the wider market may not be pricing carefully yet. Prioritise resilience first and return second by focusing on a 29 resilient stocks with low risk scores that aims to keep drawdowns more manageable when sentiment swings. Anchor your research in financial strength by working through a list of solid balance sheet and fundamentals (24 results) that filters for sturdier balance sheets and healthier fundamentals.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nektar Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681811078","isCrawlerRequest":true}